The preCARDIA system is designed to quickly treat ADHF-linked volume overload by lowering cardiac filling pressures and boosting decongestion to enhance complete cardiac and renal function.
Abiomed noted that more than one million people are admitted to hospitals with ADHF a year in the US.
Though pharmaceutical therapies are available, heart failure continues to be a major cause of hospitalisation in patients aged above 65 years.
preCARDIA offers a less invasive option to heart failure specialists. The new technology could enhance patient outcomes as well as cut down care costs by offering an early intervention.
The company’s catheter-based system comprises a superior vena cava (SVC) balloon that provides programmed intermittent occlusion of the SVC.
Enhanced response to medical management of ADHF, shorter hospital stays, fewer re-hospitalisations and better quality of life are some of the possible benefits for patients using the system.
The preCARDIA system’s design permits uncomplicated positioning by doctors and hemodynamic monitoring by medical staff.
It was granted breakthrough device designation by the US Food and Drug Administration (FDA).
An FDA early feasibility study of the system in 30 subjects showed acute technical success and substantial drop in cardiac filling pressures and rapid diuresis.
Furthermore, all the subjects were free of device or surgery-related major adverse events by 30 days.
Abiomed chairman, president and CEO Michael Minogue said: “We look forward to advancing preCARDIA’s technology through the regulatory process and expanding our relationship with heart failure specialists to help improve outcomes in early-stage, acute decompensated heart failure patients, a new patient population for Abiomed.
“This acquisition aligns with Abiomed’s principles of leading in technology and innovation and putting patients first.”
The companies have not divulged the financial terms of the deal.
In April, Abiomed enrolled the first patient in the PROTECT IV trial, which aims to obtain the clinical evidence needed to get a Class I guideline recommendation for Impella heart pumps in high-risk percutaneous coronary intervention.